Bennett Joseph J, Cao Dincai, Posner Mitchell C
Department of Surgery, University of Chicago Hospitals, Chicago, Illinois 60637, USA.
J Surg Oncol. 2005 Oct 1;92(1):64-9. doi: 10.1002/jso.20341.
Patients chosen for liver resection of colorectal liver metastases are a select group with minimal disease, favorable tumor biology and earlier presentation when compared to unresectable patients. Despite intense preoperative assessments, operative detection of occult unresectable disease is inevitable for a small group of patients. The aim of this study was to evaluate determinants of occult unresectability, and to establish if patients with occult unresectable disease demonstrate survival benefits similar to resected patients, or more similar to patients diagnosed with metastatic disease who were never explored.
A retrospective medical record review was performed on 171 patients with colorectal hepatic metastases who underwent exploration with the intent of performing a curative liver resection. Patient and tumor characteristics, operative findings and survival were evaluated. Univariate and multivariate analysis were performed to evaluate determinants of unresectability, and survival was determined by Kaplan-Meier analysis.
One hundred forty-six patients were completely resected and 25 patients were found to have occult unresectable disease during exploration. Of these 25 patients, 10 had more extensive hepatic disease than expected which precluded resection, while 15 patients had unexpected extrahepatic disease. Of the 15 patients with extrahepatic disease, 7 had otherwise resectable liver metastases. Only bilobar disease was a statistically significant finding associated with occult unresectability on multivariate analysis (P = 0.05). Resected patients had a median survival of 37 months, while unresected patients had a median survival of 17 months (P < 0.005). At 3 and 5 years, the overall survival for resected patients was 52% and 29%. The survival at 3 years for patients with occult unresectable disease was only 5%, with no 5 year survivors.
The majority of patients with occult unresectable colorectal hepatic metastases had bilobar disease or extrahepatic spread. Despite the process of patient selection that leads to an attempt for curative resection, patients with occult unresectable disease identified at exploration suffer from poor survival that approximates the outcome of patients never considered for resection.
与无法切除的患者相比,被选择进行结直肠癌肝转移灶肝切除的患者是一组疾病程度最轻、肿瘤生物学特性良好且就诊较早的特定人群。尽管进行了全面的术前评估,但仍有一小部分患者在手术中不可避免地会发现隐匿性不可切除疾病。本研究的目的是评估隐匿性不可切除的决定因素,并确定隐匿性不可切除疾病的患者是否表现出与切除患者相似的生存获益,或者更类似于从未接受探查的转移性疾病患者。
对171例接受探查以进行根治性肝切除的结直肠癌肝转移患者进行回顾性病历审查。评估患者和肿瘤特征、手术发现及生存情况。进行单因素和多因素分析以评估不可切除的决定因素,并通过Kaplan-Meier分析确定生存率。
146例患者被完全切除,25例患者在探查中发现有隐匿性不可切除疾病。在这25例患者中,10例肝脏疾病比预期更广泛,无法进行切除,而15例患者有意外的肝外疾病。在15例有肝外疾病的患者中,7例肝脏转移灶原本是可切除的。多因素分析显示,仅双侧病变是与隐匿性不可切除相关的具有统计学意义的发现(P = 0.05)。切除患者的中位生存期为37个月,而未切除患者的中位生存期为17个月(P < 0.005)。3年和5年时,切除患者的总生存率分别为52%和29%。隐匿性不可切除疾病患者3年生存率仅为5%,无5年生存者。
大多数隐匿性不可切除的结直肠癌肝转移患者有双侧病变或肝外扩散。尽管经过患者选择过程以尝试进行根治性切除,但在探查中发现的隐匿性不可切除疾病患者的生存情况较差,接近从未考虑过切除的患者的结局。